| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
As an amino acid derivative, Z-Ala-OSu does not have a defined primary drug target in the context of therapeutic development. However, as an activated ester of protected alanine, it is used in research to study peptide synthesis, enzyme-substrate interactions, and protein engineering. The Z protecting group allows for selective deprotection under hydrogenation conditions, while the OSu ester facilitates amide bond formation with amine-containing compounds. The compound can be used to synthesize alanine-containing peptides for studying protein structure and function. In peptide synthesis applications, the activated ester allows for efficient coupling reactions with minimal racemization.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro studies on amino acid derivatives, including this alanine analogue, have demonstrated their capacity to influence the release of anabolic hormones, modulate fuel availability for cellular activity, enhance mental performance under stress-related conditions, and prevent exercise-induced muscle damage. As an activated ester, this compound is primarily used in peptide synthesis rather than in direct cell-based assays. However, the peptides synthesized using this building block may be evaluated in cell-based assays to investigate their biological activities. |
| ln Vivo |
In vivo studies on amino acid derivatives have shown that they affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. As a building block for peptide synthesis, this compound is not typically administered directly in vivo. Instead, the peptides synthesized using this building block may be evaluated in animal studies for their therapeutic potential. However, specific in vivo pharmacological data for this exact compound is limited, as it is primarily supplied as a research chemical for peptide synthesis.
|
| Enzyme Assay |
Non-cell-based assays for this compound typically involve peptide coupling reactions to evaluate reactivity and coupling efficiency. Standard protocols include incubating the activated ester with amine-containing compounds (e.g., amino acids or peptide fragments) in appropriate solvents (e.g., DMF or DCM) with or without coupling additives. The progress of the reaction is monitored by TLC or HPLC, and the product is characterized by mass spectrometry or NMR. The Z protecting group allows for selective deprotection under hydrogenation conditions (H₂/Pd). The compound's ability to inhibit racemization during peptide coupling makes it valuable for synthesizing stereochemically pure peptides.
|
| Cell Assay |
Cell-based assays for this compound are not typically performed directly, as it is an activated ester used in peptide synthesis rather than a bioactive compound. However, the peptides synthesized using this building block may be evaluated in cell-based assays to investigate their biological activities. Standard cell-based protocols involve culturing cells in appropriate media at 37°C in 5% CO₂, followed by treatment with the synthesized peptides at varying concentrations (typically 0.1-100 μM) for 24-72 hours. Cell viability, signaling, or functional responses are assessed using appropriate assays.
|
| Animal Protocol |
In vivo animal studies for this compound are not typically performed directly, as it is a synthetic building block rather than a therapeutic agent. However, the peptides synthesized using this building block may be evaluated in animal studies for their therapeutic potential. Standard protocols involve administration via oral gavage, intraperitoneal injection, or intravenous injection in rodent models, with monitoring of therapeutic efficacy, pharmacokinetics, and safety. All animal studies must comply with institutional ethical guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties for this activated ester are not typically studied, as it is a synthetic building block rather than a therapeutic agent. The compound is typically consumed in peptide synthesis reactions and not administered directly in vivo. The compound shows moderate solubility in organic solvents such as DMSO and DMF. It should be stored as powder at -20°C for long-term preservation. The Z protecting group is removed by hydrogenation, while the OSu ester is reactive toward amines. Definitive PK parameters are not applicable for this compound.
|
| Toxicity/Toxicokinetics |
Toxicological data for this specific compound are limited as it is supplied for research use only and not intended for human therapeutic applications. As an activated ester, the compound is reactive and may cause skin and eye irritation upon contact. Appropriate safety precautions should be observed during handling, including the use of personal protective equipment and work in well-ventilated areas. The compound should be handled with care to avoid exposure to moisture, which can hydrolyze the activated ester. Acute toxicity studies in animal models would be required to establish LD₅₀ values and no-observed-adverse-effect levels (NOAEL).
|
| References | |
| Additional Infomation |
Z-Ala-OSu is an alanine derivative featuring a benzyloxycarbonyl (Z or Cbz) protecting group and a N-hydroxysuccinimide (OSu) activated ester. It is a valuable building block in the synthesis of peptides, enabling researchers to create custom peptides for various applications in drug development and biotechnology. The activated ester allows for efficient coupling reactions with amine-containing compounds with minimal racemization, making it useful for synthesizing stereochemically pure peptides. It is not an approved drug and has not undergone clinical trials; it is strictly for research purposes.
|
| Molecular Formula |
C15H16N2O6
|
|---|---|
| Molecular Weight |
320.30
|
| Exact Mass |
320.1
|
| CAS # |
3401-36-3
|
| PubChem CID |
837751
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Melting Point |
119-123ºC
|
| Index of Refraction |
1.580
|
| LogP |
0.19
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
23
|
| Complexity |
470
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C[C@H](NC(OCC1=CC=CC=C1)=O)C(ON2C(CCC2=O)=O)=O
|
| InChi Key |
OFIYNISEFIEQBC-JTQLQIEISA-N
|
| InChi Code |
InChI=1S/C15H16N2O6/c1-10(14(20)23-17-12(18)7-8-13(17)19)16-15(21)22-9-11-5-3-2-4-6-11/h2-6,10H,7-9H2,1H3,(H,16,21)/t10-/m0/s1
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) (2S)-2-(phenylmethoxycarbonylamino)propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 20 mg/mL (62.44 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1221 mL | 15.6104 mL | 31.2207 mL | |
| 5 mM | 0.6244 mL | 3.1221 mL | 6.2441 mL | |
| 10 mM | 0.3122 mL | 1.5610 mL | 3.1221 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
